Valuation: Recursion Pharmaceuticals, Inc.

Market Cap 2.27B 2.03B 1.88B 1.7B 3.18B 216B 3.24B 22.62B 8.95B 113B 8.53B 8.34B 358B P/E 2026 *
-4.29x
P/E 2027 * -4.37x
Enterprise Value 1.82B 1.63B 1.5B 1.36B 2.55B 173B 2.59B 18.1B 7.16B 90.49B 6.82B 6.68B 287B EV / Sales 2026 *
43.5x
EV / Sales 2027 * 36.1x
Free-Float
98.17%
Yield 2026 *
-
Yield 2027 * -
1 day+1.18%
1 week+5.60%
Current month-6.42%
1 month+4.46%
3 months+28.41%
6 months+11.06%
Current year-5.50%
1 week 3.45
Extreme 3.45
3.87
1 month 3.44
Extreme 3.44
5.19
Current year 2.77
Extreme 2.77
5.24
1 year 2.77
Extreme 2.77
6.25
3 years 2.77
Extreme 2.77
15.74
5 years 2.77
Extreme 2.77
21.19
10 years 2.77
Extreme 2.77
42.81
Manager TitleAgeSince
Chief Executive Officer 43 01/01/2026
Director of Finance/CFO 48 20/11/2024
Chief Tech/Sci/R&D Officer 57 06/04/2026
Director TitleAgeSince
Director/Board Member 44 04/11/2013
Director/Board Member 62 04/11/2013
Director/Board Member 37 01/09/2016
Date Insider Type Main position Quantity % Market Cap. Importance
10/6/26 A Sell

Founder

-50,000 0.0093%
10/6/26 A Exercice

Director

75,000 0.0140%
10/1/26 A Free

Director

4,607 0.0009%
Change 5-day change 1-year change 3-year change Capi.($)
+1.18%+5.60%-38.65%-26.80% 2.27B
+0.88%-0.34%+40.64%+73.05% 65.28B
-0.79%-0.77%+8.95%+76.11% 54.57B
-0.76%+0.67%+8.75%+100.00% 53.59B
+0.22%+5.55%+30.03%+57.12% 45.03B
-3.27%-7.41%+12.87%+108.87% 42.17B
-0.86%-6.69%+216.25%+885.45% 39.42B
-2.26%-4.14%+15.38%+45.53% 32.71B
-2.70%-10.77%+19.80%-6.47% 24.01B
+0.17%+14.45%+59.25%+48.38% 26.5B
Average -0.77%+2.67%+37.33%+136.12% 38.55B
Weighted average by Cap. -0.77%+2.29%+42.77%+152.77%

Financials

2026 *2027 *
Net sales 41.78M 37.36M 34.57M 31.3M 58.58M 3.98B 59.54M 416M 165M 2.08B 157M 153M 6.58B 53.03M 47.42M 43.87M 39.72M 74.34M 5.04B 75.56M 528M 209M 2.64B 199M 195M 8.35B
Net income -466M -417M -386M -349M -654M -44.38B -665M -4.64B -1.84B -23.21B -1.75B -1.71B -73.49B -506M -452M -418M -379M -709M -48.1B -720M -5.03B -1.99B -25.16B -1.9B -1.86B -79.66B
Net Debt -453M -405M -375M -340M -635M -43.13B -646M -4.51B -1.79B -22.56B -1.7B -1.66B -71.42B -359M -321M -297M -269M -504M -34.17B -512M -3.58B -1.41B -17.87B -1.35B -1.32B -56.59B
Projected Income Statement - Annual - Recursion Pharmaceuticals, Inc.
Logo Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.
Employees
600
Date Price Change Volume
27/10/26 $3.845 +1.18% 1,744,017
26/10/26 $3.800 +2.70% 16,104,057
23/10/26 $3.700 +3.35% 19,075,336
22/10/26 $3.580 -1.65% 17,735,730
21/10/26 $3.640 -0.55% 19,356,539
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Recursion Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
3.800USD
Average target price
7.317USD
Spread / Average Target
+92.54%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Recursion Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. RXRX Stock